Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Diabetes mellitus is a growing global disease now and future, and in China, 1.2 million
peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is
Type 2 diabetes mellitus. Glipizide is a potent drug to service patients who suffer from Type
2 disease. Little information has been presented for the relationship between CYP2C19 genetic
polymorphism and glipizide, since recently the investigators reported that there existed a
tendency. In this study the investigators found that CYP2C19 polymorphism significantly
influenced the pharmacokinetics of glipizide.